STS: Parents of CHD Children ID Important Outcome Measures

Share this content:
STS: Parents of CHD Children ID Important Outcome Measures
STS: Parents of CHD Children ID Important Outcome Measures

TUESDAY, Jan. 24, 2017 (HealthDay News) -- Parents of children with congenital heart disease (CHD) feel that survival statistics, surgeon-specific experience, and complication rates are the most important outcome measures for public reporting, according to a study presented at the annual meeting of the Society of Thoracic Surgeons, held from Jan. 21 to 25 in Houston.

Mallory L. Irons, M.D., from the Hospital of the University of Pennsylvania in Philadelphia, and colleagues developed a 43-item questionnaire to gauge parent attitudes regarding the format and content of an ideal public reporting scheme. The authors then surveyed parents of children with CHD, with complete data from 1,281 survey responses.

The researchers found that parents identified survival statistics, surgeon-specific experience, and complications rates as most important when asked to rank categories of outcome measures or other type of information to include in an optimal public reporting scheme. Most parents (89 percent) identified a numerical procedure-based approach as the best format for hospital-specific mortality rates; 60 percent reported that the hospital star rating system was the worst potential format to display mortality data.

"Our research emphasized that parents have valuable opinions about the content and format of the information that should be provided," Irons said in a statement. "How data are presented may be more important than the data itself, with the type of visual display employed affecting the degree to which parents correctly interpret the data presented."

Abstract - Page 38
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »